Skip to main content
Premium Trial:

Request an Annual Quote

Lentigen Extends Army Program for Lentiviral Biodefense

NEW YORK (GenomeWeb News) – Lentigen has signed a contract with the US Army that extends a 2006 agreement that uses the company’s lentiviral vector technology for biodefense, the company said today.
 
The Army will use the lentiviral technology, which is used to deliver genes or gene silencing sequences into cells, at its Edgewood Chemical Biological Center.
 
Lentigen CSO Boro Dropulic said the technology has been successful in helping to produce an antibody targeted to anthrax. The lentiviral technology also has been used to produce “difficult-to-express proteins at levels suitable for further development and potential commercialization,” Dropulic added.
 
“The unique capabilities of these extraordinary vectors could enhance the production of cellular products used in so many aspects of our development programs,” Army Scientific Advisor for Biotechnology James Valdes said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.